Metalmark

Orgenesis Announces Name Change of Morgenesis Business Unit to Octomera

Retrieved on: 
Tuesday, July 11, 2023
GMP, Partnership, Network, CGT, Hospital, CGMP, Investment, Patient, MM, Growth, Metalmark Capital, Metalmark, Vaccine, Cryptocurrency, Labs, Fausto Pocar

Morgenesis was originally formed in 2022 to separate Orgenesis’ existing POCare Service and supply solutions from the other operations of Orgenesis.

Key Points: 
  • Morgenesis was originally formed in 2022 to separate Orgenesis’ existing POCare Service and supply solutions from the other operations of Orgenesis.
  • A new Octomera website and rebranding will be unveiled throughout the second half of 2023.
  • The capital from the MM investment is for the continued development of POCare Centers with a focus on expanding in the US market.
  • Octomera is focused on changing the paradigm of centralized cell and gene therapy (CGT) production to produce treatments in a decentralized point of care manner.

Orgenesis Provides Business Update for the First Quarter of 2023 and Reports Continued Progress on its POCare Strategy

Retrieved on: 
Wednesday, May 10, 2023
GMP, CGT, Marketing, Government, Security (finance), Cryptocurrency, Metalmark, Fausto Pocar

(NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for the first quarter ended March 31, 2023.

Key Points: 
  • (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for the first quarter ended March 31, 2023.
  • Vered Caplan, CEO of Orgenesis, said, “We achieved revenue of approximately $7.0 million for the first quarter of 2023, which reflects the continued progress of our POCare strategy.
  • We are currently focused on the implementation of our quality systems, as well as our GMP processes at the various POCare sites.
  • We are also expanding our international management team with the support of Metalmark, our long-term partner and investor in our Morgenesis subsidiary.

Orgenesis Secures an Additional $5 Million Investment from Metalmark Capital to Accelerate Growth of Point-of-Care Service Subsidiary

Retrieved on: 
Wednesday, May 10, 2023
CGT, Securities and Exchange Commission of Pakistan, CGMP, Patient, DSM-IV codes, Growth, Security (finance), Metalmark Capital, Therapy, Fausto Pocar, Pharmaceutical industry, Management, Metalmark

This investment follows the previously announced investment of $30 million in November 2022.

Key Points: 
  • This investment follows the previously announced investment of $30 million in November 2022.
  • In addition, Metalmark has committed to investing up to an additional $15 million, subject to the achievement of certain milestones.
  • This additional investment will further propel our growth as we expand our global operations and add key personnel, enabling us to capitalize on the substantial demand for our POCare services.
  • Morgenesis will use the additional capital to support the development of additional POCare Centers, as well as the OMPULs in both the U.S. and international markets.

Orgenesis Achieves Revenue of $8.0 Million for the Third Quarter of 2022

Retrieved on: 
Thursday, November 10, 2022
Protest and strikes of the CGT union 2021, GLOBE, Hospital, Contract, CDMO, U.S. Securities and Exchange Commission, CGT, Diabetes, Telephone, Research, Metalmark Capital, Technology, An Act to exempt a particular class of securities from the Securities and Exchange Act, COVID-19, Securities Act of 1933, Therapy, Annual report, NASDAQ, JV, RISK, Company, Conference, Patient, CEO, Security (finance), Energy Independence and Security Act of 2007, Industry, Metalmark, Income, Nightclub, Pharmaceutical industry, Labs, Fausto Pocar

GERMANTOWN, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for third quarter ending September 30, 2022.

Key Points: 
  • Orgenesis to Host Conference Call on Friday, November 11, 2022 at 8:00 AM Eastern Time
    GERMANTOWN, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc .
  • Vered Caplan, CEO of Orgenesis, said, We have made significant progress in advancing the rollout of our POCare platform.
  • This transaction was highly strategic for the Company and we believe that it provides further validation of our business model.
  • While we are pleased to have achieved revenue of approximately $8.0 million for the third quarter, we were limited by capital constraints.

Orgenesis Secures up to $50 Million Subsidiary-Level Investment from Metalmark Capital to Accelerate Growth of Point-of-Care Services

Retrieved on: 
Monday, November 7, 2022
RISK, Metalmark Capital, Company, Research, LLC, Growth, Investment, Hospital, CGMP, JV, GLOBE, Diversified Pharmaceutical Services, History, Wardwell, COVID-19, Patient, LLP, Therapy, William Blair & Company, CEO, Securities Act of 1933, Annual report, U.S. Securities and Exchange Commission, Metalmark, NASDAQ, Drug Quality and Security Act, Partnership, An Act to exempt a particular class of securities from the Securities and Exchange Act, Diabetes, Technology, Security (finance), United, P.C, Achievement, Protest and strikes of the CGT union 2021, CGT, Solution, Pharmaceutical industry, Financial adviser, Labs, Fausto Pocar

The initial investment of $30 million will consist of $20 million in cash and conversion of the convertible loan Metalmark previously provided to Morgenesis in August 2022.

Key Points: 
  • The initial investment of $30 million will consist of $20 million in cash and conversion of the convertible loan Metalmark previously provided to Morgenesis in August 2022.
  • We are excited to partner with Vered Caplan and the entire Morgenesis team, said Howard Hoffen, Chairman and CEO of Metalmark.
  • We have selected Metalmark Capital as a partner in the POCare services subsidiary for their history of investment and success in the pharmaceutical services sector.
  • William Blair & Company, LLC served as exclusive financial advisor to Metalmark and Davis Polk & Wardwell, LLP served as legal counsel to Metalmark.

Orgenesis Achieves Revenue of $7.2 Million for the Second Quarter of 2022

Retrieved on: 
Tuesday, August 16, 2022
Telephone, Metalmark, Energy Independence and Security Act of 2007, RISK, U.S. Securities and Exchange Commission, Cell, Industry, CEO, GLOBE, Technology, Growth, Regenerative medicine, Hospital, Protest and strikes of the CGT union 2021, Potency (pharmacology), Research, Annual report, Security (finance), Government, Patient, 8-K, Therapy, COVID-19, Company, Contract, NASDAQ, University of Maryland Center for Environmental Science, Â, An Act to exempt a particular class of securities from the Securities and Exchange Act, Johns Hopkins, Securities Act of 1933, JV, Diabetes, Metalmark Capital, CGT, Conference, Pharmaceutical industry, Online shopping, Fausto Pocar, Labs

GERMANTOWN, Md., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for second quarter ending June 30, 2022.

Key Points: 
  • Orgenesis to Host Conference Call Today, August 16, 2022 at 11 AM Eastern Time
    GERMANTOWN, Md., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc .
  • (NASDAQ: ORGS) (Orgenesis or the Company), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for second quarter ending June 30, 2022.
  • Vered Caplan, CEO of Orgenesis, said, We are progressing with our transition to the second phase of the planned rollout of our POCare platform.
  • This includes revenue generation from the validation, process development, and supply of advanced therapies that utilize our POCare platform and Orgenesis Mobile Processing Units and Labs (OMPULs).

Audax Private Debt Provides Financing to Support Add-On Acquisitions for Metalmark Capital’s Portfolio Company, Innovetive Petcare

Retrieved on: 
Thursday, February 3, 2022
Professional Services, Health, Veterinary, Finance, CEO, Chief executive officer, General practice, Audax, Metalmark, Credit, Metalmark Capital, Animal, Consumer, Company, LinkedIn, Solution, Financial services, Veterinary medicine, Security (finance), Innovetive Petcare, Audax Private Debt, Metalmark Capital, INNOVETIVE PETCARE, AUDAX PRIVATE DEBT, METALMARK CAPITAL

Audax Private Debt announced that, as Administrative Agent and Sole Lead Arranger, it provided an incremental Second Lien Credit Facility to support add-on acquisitions by Metalmark Capitals portfolio company, Innovetive Petcare (Innovetive or the Company), a leading operator of veterinary practices.

Key Points: 
  • Audax Private Debt announced that, as Administrative Agent and Sole Lead Arranger, it provided an incremental Second Lien Credit Facility to support add-on acquisitions by Metalmark Capitals portfolio company, Innovetive Petcare (Innovetive or the Company), a leading operator of veterinary practices.
  • Innovetive has consistently provided best-in-class services and solutions through its growing base of veterinary clinics, said Shehzad Ajmal, Managing Director at Audax Private Debt.
  • Audax Private Debt has been a reliable and engaged financing partner for us, said Howard Hoffen, Chairman & CEO of Metalmark.
  • Based in New York, Audax Private Debt is a leading debt capital partner for North American middle market companies.

Metalmark Announces New Strategic Investment Fund to Support Continued Growth of Innovetive Petcare, a Leading Veterinary Services Provider

Retrieved on: 
Tuesday, January 18, 2022
Banking, Professional Services, Finance, Davis Polk & Wardwell, Growth, LLP, Jefferies Group, Creativity, PETS, Company, Capital, Lexington Partners, Metalmark Capital, Veterinary medicine, Wardwell, Metalmark, LLC, Hospital, Partnership, Financial services

Metalmark Capital (Metalmark), a leading private equity firm, announced that it has raised new capital to support the continued growth of Innovetive Petcare (Innovetive or the Company).

Key Points: 
  • Metalmark Capital (Metalmark), a leading private equity firm, announced that it has raised new capital to support the continued growth of Innovetive Petcare (Innovetive or the Company).
  • The continuation fund broadens and strengthens Innovetives investor base while providing significant capital to support Innovetive's next chapter of growth.
  • The continuation fund is led by Glendower Capital and funds advised by Neuberger Berman, with participation from other leading secondary investors.
  • Headquartered in Austin, Texas, Innovetive is a leading acquirer and operator of veterinary practices.

Amplitude Healthcare Acquisition Corporation Announces Shareholder Approval of Business Combination with Jasper Therapeutics, Inc.

Retrieved on: 
Wednesday, September 22, 2021
Therapy, Probability, Failure, Business architecture, Bone marrow, Degenerative disease, Annual report, Security (finance), U.S. Securities and Exchange Commission, Carma, Patient, Nasdaq, Population, Physician, Lists of diseases, Business, Biology, Private Securities Litigation Reform Act, Industry, Acquisition, Risk, COVID-19, Stem cell, PIPE, Forward-looking statement, Safety, Investment, Metalmark, NEW, SEC, GLOBE, Pharmaceutical industry

REDWOOD CITY, Calif. and NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Amplitude Healthcare Acquisition Corporation (Nasdaq: AMHC) (“AMHC”), a special purpose acquisition company, today announced that its stockholders voted to approve the previously announced business combination (the “Business Combination”) with Jasper Therapeutics, Inc. (“Jasper”), a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell, and all other proposals presented at AMHC’’s special shareholder’s meeting held on September 22, 2021.

Key Points: 
  • AMHCs shareholders approved the Business Combination proposal with 74.9% votes in favor of the approximately 9,872,643 AMHC votes cast at the meeting.
  • Holders of 9,262,099 shares of AMHC Class A common stock have elected to redeem their shares in connection with the Business Combination.
  • Subject to the satisfaction or waiver of the other customary closing conditions, the Business Combination is expected to close on or about September 24, 2021.
  • AMHC and Jasper Therapeutics anticipate that subsequent events and developments will cause AMHCs and Jasper Therapeutics assessments to change.

Jasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Two New Board Members

Retrieved on: 
Monday, September 20, 2021
Biotechnology, Health, Genetics, Stem Cells, Pharmaceutical, Biochemistry, CRISPR Therapeutics, Biophysics, Therapy, Global, Metalmark Capital, Securities Act of 1933, CRISPR, Failure, San Diego State University, University of Wisconsin–Madison, Physics, SPAC, Bone marrow, Degenerative disease, Proxy, Person, Ernst, Sale, Doctor of Philosophy, U.S. Securities and Exchange Commission, Carma, Patient, Lists of diseases, PricewaterhouseCoopers, Form, Biology, Retail Industry Leaders Association, Industry, Acquisition, University, Communication, Company, LLC, Bloomberg Industry Group, Audit committee, McKinsey & Company, Stanford University, Risk, Stem cell, EY, Forward-looking statement, Investment, Prospectus, Ernst & Young, Nasdaq, Metalmark, SEC, Pharmaceutical industry, Management, Security (finance), Jasper Therapeutics, Amplitude Healthcare Acquisition Corporation, JASPER THERAPEUTICS, AMPLITUDE HEALTHCARE ACQUISITION CORPORATION

Neither Jasper Therapeutics, Inc. nor Amplitude Healthcare Acquisition Corporation gives any assurance that either Jasper Therapeutics, Inc. or Amplitude Healthcare Acquisition Corporation will achieve its expectations.

Key Points: 
  • Neither Jasper Therapeutics, Inc. nor Amplitude Healthcare Acquisition Corporation gives any assurance that either Jasper Therapeutics, Inc. or Amplitude Healthcare Acquisition Corporation will achieve its expectations.
  • In connection with the proposed business combination between Jasper Therapeutics, Inc. and Amplitude Healthcare Acquisition Corporation, the registration statement on Form S-4 has been declared effective by the SEC.
  • That registration statement includes the related proxy statement and prospectus of Amplitude Healthcare Acquisition Corporation with respect to Amplitude Healthcare Acquisition Corporations special meeting of stockholders.
  • In addition, the documents filed by Amplitude Healthcare Acquisition Corporation may be obtained free of charge by directing a request to Amplitude Healthcare Acquisition Corporation, 1177 Avenue of the Americas, Fl 40, New York, New York 10036.